GSK Presents Results of Daprodustat in P-III ASCEND Program for the Treatment of Anemia due to Chronic Kidney Disease at ASN Kidney Week 2021
Shots:
- The P-III ASCEND program includes 5 studies i.e ASCEND-ND, D, ID, NHQ & TD studies evaluating efficacy & safety of daprodustat vs ESA in ~8,000 patients with anemia due to CKD for ~ 4.26yrs.
- The ASCEND-ND & D studies met its 1EPs i.e., the therapy was improved or maintained Hg within the target range. The prespecified primary safety analysis of the ITT population showed similar rates of MACE & achieved non-inferiority without increased CV risk compared to ESA
- Additionally, the results also showed an improvement in Hb levels in non-dialysis patients & QoL in the ASCEND-NHQ trial compared to PBO & maintain Hb levels in high-risk incident dialysis population in the ASCEND-ID trial
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com